Selskabets formål er import, marketing, emballering, salg, distribution, forskning, udvikling og produktion af medicinalprodukter og andre former for medicinalrelaterede produkter, herunder også medicinal uddannelse, samt al virksomhed, som efter bestyrelsens skøn er beslægtet hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 174.3 mio. | 5.9 mio. | 101.3 mio. | 60 mio. | 10 | |
CVR: 30899032
Compared to 156 companies in Agenturhandel med specialiseret varesortiment, bortset fra køretøjer
Comparison is based on industry median values
Companies in the same industry and area
CVR 26308836
CVR 82591419
CVR 25784723
CVR 39975750
CVR 42290025
Gilead Sciences Denmark ApS demonstrates a solid financial health with a notable increase in revenue and profit over the past year. In 2024, the company reported revenue of 174.3 million DKK and a profit of 5.9 million DKK, reflecting a growth from 109.9 million DKK in revenue and 3.2 million DKK in profit in 2023. The equity position has also improved, rising to 60 million DKK, indicating a strengthening balance sheet. Despite fluctuations in revenue over the past few years, the overall trend suggests stability and growth potential within the specialized goods trading industry. However, the company's reliance on a narrow product range could pose risks if market conditions shift.
AI-generated summary
companydata.dk